Mainz Biomed Ownership
| MYNZ Stock | USD 4.80 0.53 12.41% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 21.2 M | Current Value 17.7 M | Avarage Shares Outstanding 13.1 M | Quarterly Volatility 5 M |
Mainz |
Mainz Stock Ownership Analysis
The company has price-to-book ratio of 1.72. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mainz Biomed BV recorded a loss per share of 44.4. The entity had not issued any dividends in recent years. The firm had 1:40 split on the 3rd of December 2024. Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic and research use only tests for clinical diagnostics in human genetics. The company was founded in 2008 and is based in Mainz, Germany. Mainz Biomed is traded on NASDAQ Exchange in the United States. To find out more about Mainz Biomed BV contact Guido Baechler at 49 6131 554 2860 or learn more at https://mainzbiomed.com.Besides selling stocks to institutional investors, Mainz Biomed also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Mainz Biomed's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Mainz Biomed's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Mainz Biomed Quarterly Liabilities And Stockholders Equity |
|
About 5.0% of Mainz Biomed BV are currently held by insiders. Unlike Mainz Biomed's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Mainz Biomed's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Mainz Biomed's insider trades
Mainz Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mainz Biomed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mainz Biomed BV backward and forwards among themselves. Mainz Biomed's institutional investor refers to the entity that pools money to purchase Mainz Biomed's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-12-31 | 222 K | Virtu Financial Llc | 2024-12-31 | 18.3 K | Ubs Group Ag | 2024-12-31 | 3.8 K | Citigroup Inc | 2024-12-31 | 673 | Newbridge Financial Services Group, Inc. | 2024-12-31 | 500 | Sbi Securities Co Ltd | 2024-12-31 | 61.0 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 4.0 |
Mainz Biomed Outstanding Bonds
Mainz Biomed issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mainz Biomed BV uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mainz bonds can be classified according to their maturity, which is the date when Mainz Biomed BV has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Mainz Biomed Corporate Filings
6K | 13th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 16th of December 2024 Other Reports | ViewVerify | |
| 11th of December 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Mainz Stock Analysis
When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.